Track this trial free. DataLookout checks ClinicalTrials.gov daily and emails you which fields changed on NCT06750783 (status, enrollment, completion dates, endpoints, sites) when this record is updated. Free accounts track up to 5 trials.

Track this trial

The Effects of Xuezhikang and Atorvastatin on Lipid in Patients With Dyslipidemia and Prediabetes

Study acronym: Xuezhikang
StatusRecruiting
PhasePhase 4
Started
View on ClinicalTrials.gov ↗
Record status
This record was last updated April 3, 2025 (before its estimated March 31, 2026 completion). Its status may not reflect the trial's current state.

Record History

See every version on ClinicalTrials.gov ↗

  1. Site contacts updated at 1 of 3 sites
    • Study title revised
    v3
  2. Eligibility criteria shortened, about 15 words
    • Site contacts updated at 1 of 3 sites
    v2
  3. Study First Submitted
  • Stopped: an ongoing trial was terminated, suspended or withdrawn.
  • Notable: the trial’s plan changed such as a big move in its timeline or size, a new primary endpoint, sponsor or phase, or recruiting opened or resumed.
  • Minor: routine progress and housekeeping, such as sites added or enrollment closed.
This study compares the impact of Xuezhikang and atorvastatin on glucose metabolism to explore the incidence of prediabetes patients developing diabetes after 24 weeks of Xuezhikang use, and by investigating the effect of Xuezhikang on blood glucose fluctuations, discusses the possible mechanisms by which Xuezhikang affects glucose metabolism.
Trial Details
NCT Number NCT06750783
Lead Sponsor Beijing Tsinghua Chang Gung Hospital
Conditions
(from sponsor)		 Prediabetic State (IGT)
Related terms Diabetes Mellitus, Prediabetic State
Enrollment 398 participants
Start Date
Primary Completion (estimated)
Study Completion (estimated)
Updated on ClinicalTrials.gov